These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

105 related items for PubMed ID: 16079529

  • 1. Optimization of imidazole 5-lipoxygenase inhibitors and selection and synthesis of a development candidate.
    Mano T, Stevens RW, Ando K, Kawai M, Kawamura K, Nakao K, Okumura Y, Okumura T, Sakakibara M, Miyamoto K, Tamura T.
    Chem Pharm Bull (Tokyo); 2005 Aug; 53(8):965-73. PubMed ID: 16079529
    [Abstract] [Full Text] [Related]

  • 2. 4-[5-Fluoro-3-[4-(2-methyl-1H-imidazol-1-yl)benzyloxy]phenyl]-3,4,5,6- tetrahydro-2H-pyran-4-carboxamide, an orally active inhibitor of 5-lipoxygenase with improved pharmacokinetic and toxicology characteristics.
    Mano T, Okumura Y, Sakakibara M, Okumura T, Tamura T, Miyamoto K, Stevens RW.
    J Med Chem; 2004 Jan 29; 47(3):720-5. PubMed ID: 14736252
    [Abstract] [Full Text] [Related]

  • 3. Synthesis and SAR study of 4,5-diaryl-1H-imidazole-2(3H)-thione derivatives, as potent 15-lipoxygenase inhibitors.
    Assadieskandar A, Amini M, Salehi M, Sadeghian H, Alimardani M, Sakhteman A, Nadri H, Shafiee A.
    Bioorg Med Chem; 2012 Dec 15; 20(24):7160-6. PubMed ID: 23117172
    [Abstract] [Full Text] [Related]

  • 4. 5-Lipoxygenase inhibitors: convenient synthesis of 4-[3-(4-heterocyclylphenylthio)phenyl]-3,4,5,6-tetrahydro-2H-pyran-4-carboxamide analogues.
    Mano T, Stevens RW, Okumura Y, Kawai M, Okumura T, Sakakibara M.
    Bioorg Med Chem Lett; 2005 May 16; 15(10):2611-5. PubMed ID: 15863327
    [Abstract] [Full Text] [Related]

  • 5. Discovery of selective imidazole-based inhibitors of mammalian 15-lipoxygenase: highly potent against human enzyme within a cellular environment.
    Weinstein DS, Liu W, Ngu K, Langevine C, Combs DW, Zhuang S, Chen C, Madsen CS, Harper TW, Robl JA.
    Bioorg Med Chem Lett; 2007 Sep 15; 17(18):5115-20. PubMed ID: 17656086
    [Abstract] [Full Text] [Related]

  • 6. Novel imidazole compounds as a new series of potent, orally active inhibitors of 5-lipoxygenase.
    Mano T, Stevens RW, Ando K, Nakao K, Okumura Y, Sakakibara M, Okumura T, Tamura T, Miyamoto K.
    Bioorg Med Chem; 2003 Sep 01; 11(18):3879-87. PubMed ID: 12927848
    [Abstract] [Full Text] [Related]

  • 7. Nonsteroidal anti-inflammatory drugs as scaffolds for the design of 5-lipoxygenase inhibitors.
    Kolasa T, Brooks CD, Rodriques KE, Summers JB, Dellaria JF, Hulkower KI, Bouska J, Bell RL, Carter GW.
    J Med Chem; 1997 Feb 28; 40(5):819-24. PubMed ID: 9057869
    [Abstract] [Full Text] [Related]

  • 8. Substituted thiopyrano[2,3,4-c,d]indoles as potent, selective, and orally active inhibitors of 5-lipoxygenase. Synthesis and biological evaluation of L-691,816.
    Hutchinson JH, Riendeau D, Brideau C, Chan C, Delorme D, Denis D, Falgueyret JP, Fortin R, Guay J, Hamel P.
    J Med Chem; 1993 Sep 17; 36(19):2771-87. PubMed ID: 8410991
    [Abstract] [Full Text] [Related]

  • 9. In vitro-in vivo correlation and translation to the clinical outcome for CJ-13,610, a novel inhibitor of 5-lipoxygenase.
    Matthew Hutzler J, Linder CD, Melton RJ, Vincent J, Daniels JS.
    Drug Metab Dispos; 2010 Jul 17; 38(7):1113-21. PubMed ID: 20375180
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. CJ-13610, an orally active inhibitor of 5-lipoxygenase is efficacious in preclinical models of pain.
    Cortes-Burgos LA, Zweifel BS, Settle SL, Pufahl RA, Anderson GD, Hardy MM, Weir DE, Hu G, Happa FA, Stewart Z, Muthian S, Graneto MJ, Masferrer JL.
    Eur J Pharmacol; 2009 Sep 01; 617(1-3):59-67. PubMed ID: 19580807
    [Abstract] [Full Text] [Related]

  • 12. Pharmacology of PF-4191834, a novel, selective non-redox 5-lipoxygenase inhibitor effective in inflammation and pain.
    Masferrer JL, Zweifel BS, Hardy M, Anderson GD, Dufield D, Cortes-Burgos L, Pufahl RA, Graneto M.
    J Pharmacol Exp Ther; 2010 Jul 01; 334(1):294-301. PubMed ID: 20378715
    [Abstract] [Full Text] [Related]

  • 13. Comparative protection against liver inflammation and fibrosis by a selective cyclooxygenase-2 inhibitor and a nonredox-type 5-lipoxygenase inhibitor.
    Horrillo R, Planagumà A, González-Périz A, Ferré N, Titos E, Miquel R, López-Parra M, Masferrer JL, Arroyo V, Clària J.
    J Pharmacol Exp Ther; 2007 Dec 01; 323(3):778-86. PubMed ID: 17766677
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Design and synthesis of pyrimido[4,5-b][1,4]benzothiazine derivatives, as potent 15-lipoxygenase inhibitors.
    Bakavoli M, Nikpour M, Rahimizadeh M, Saberi MR, Sadeghian H.
    Bioorg Med Chem; 2007 Mar 01; 15(5):2120-6. PubMed ID: 17210254
    [Abstract] [Full Text] [Related]

  • 17. Imidazo[2,1-b]thiazole derivatives as new inhibitors of 15-lipoxygenase.
    Tehrani MB, Emami S, Asadi M, Saeedi M, Mirzahekmati M, Ebrahimi SM, Mahdavi M, Nadri H, Moradi A, Moghadam FH, Farzipour S, Vosooghi M, Foroumadi A, Shafiee A.
    Eur J Med Chem; 2014 Nov 24; 87():759-64. PubMed ID: 25310714
    [Abstract] [Full Text] [Related]

  • 18. Structural optimization and biological evaluation of 2-substituted 5-hydroxyindole-3-carboxylates as potent inhibitors of human 5-lipoxygenase.
    Karg EM, Luderer S, Pergola C, Bühring U, Rossi A, Northoff H, Sautebin L, Troschütz R, Werz O.
    J Med Chem; 2009 Jun 11; 52(11):3474-83. PubMed ID: 19492852
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.